Vireo Growth (VREOF) EBT Margin (2020 - 2026)

Vireo Growth (VREOF) posted EBT Margin of 3.95% for Q1 2026, up 65.69% sequentially from 11.53% in Q4 2025, and up 1564.0% YoY from 0.24% in Q1 2025.

Vireo Growth (VREOF) EBT Margin (2020 - 2026) Analysis & Trends

Vireo Growth has reported EBT Margin for 7 years, with the latest figure at 3.95% in Q1 2026.

Quarterly EBT Margin rose 1564.0% year-over-year to 3.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.21% (up 776.0% YoY) and the FY2025 annual result came in at 14.85%, up 215.0% from the prior year.
EBT Margin advanced to 3.95% in Q1 2026 per VREOF's latest filing, from 11.53% in the prior quarter.
Over five years, EBT Margin peaked at 0.91% in Q2 2024 and troughed at 104.27% in Q1 2022.
A 5-year average of 25.42% and a median of 19.59% in 2025 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 6351 bps in 2022, then surged 6894 bps in 2023.
Over 5 years, EBT Margin stood at 38.52% in 2022, then surged by 61 bps to 14.87% in 2023, then plunged by 205 bps to 45.39% in 2024, then surged by 75 bps to 11.53% in 2025, then surged by 66 bps to 3.95% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 3.95%, 11.53%, and 14.13% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	-10.99%
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	13.34%
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	47.58%
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	-1.70%
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	16.91%
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	4.09%
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Vireo Growth	491.44 Mn	349.14 Mn	95.30 Mn	6.78%

Download Data